Navigation Links
Northwest Secures US$4.0 Million in Debt Financing
Date:5/9/2008

sis. The Company has two broad platform technologies: dendritic cell-based vaccines, and therapeutic antibodies. The Company is currently conducting a large clinical trial in Glioblastoma multiforme, which is designed and powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company has started, and is currently enrolling patients in, a Phase I/II trial with DCVax(R) for recurrent ovarian cancer. The Company also has a second technology platform, involving monoclonal antibodies to CXCR4, which is at the late pre-clinical development stage.

For further information, please visit the company web site at http://www.nwbio.com.

About the Al Rajhi Group

Al Rajhi Holdings W.L.L. and Al Rajhi Partners (together "Al Rajhi") represent the business interests of Sheikh Abdulrahman Saleh Al Rajhi and his immediate family in Saudi Arabia.

Al Rajhi is a private investment company and has investments in financial services, infrastructure, mining, healthcare, biotechnology, real estate, oil and gas. Key investments include Bank Al Bilad, DanaGas, Saudi Telecom, Saudi Cement and Procare hospitals. Khalid al Rajhi, CEO of Al Rajhi, is a director of each of these companies.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning the Company's plans to move its programs forward, statements regarding the Company's clinical trials and other business development activities, and statements regarding its fundraising activities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially fro
'/>"/>

SOURCE Northwest Biotherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
2. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
3. Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics
4. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
5. D-Pharm Secures Funding From Israels Chief Scientists Office
6. Aerovance Secures $20 Million in Debt Financing
7. Amarin Secures Global Intellectual Property Rights for Lipid Programs
8. Ranier Technology Secures GBP8m Funding for its Cadisc Replacement Spinal Discs
9. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
10. Taligen Therapeutics Secures Series B Financing
11. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... successful completion of a field clinical study of its canine osteoarthritis stem cell ... with Aratana Therapeutics (Kansas City, KS) and will be marketed in the US ...
(Date:7/30/2015)... LOUIS, July 30, 2015 HIGHLIGHTS:Q2 ... in 2014) , Reported sales were $697 million ... 2014.  Sales grew organically by 8%, and changes in ... acquisitions increased sales by 1%. , By business ... in Applied and 11% in SAFC Commercial. , ...
(Date:7/29/2015)... , July 30, 2015 ... la santé, publie ses résultats pour le premier ... commente les résultats. Visionner l,interview ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de ... - Moteurs de croissance - ...
(Date:7/29/2015)...  HealthSouth Corporation (NYSE: HLS ), ... healthcare services, offering both facility-based and home-based post-acute ... the second quarter ended June 30, 2015. ... volume growth in both segments and an 11.0% ... President and Chief Executive Officer of HealthSouth. "While ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15
... Tumor Protection In Vivo; Lead Candidate May Have Utility ... ... SAN DIEGO, CA, Sept. 24 /PRNewswire-FirstCall/ - Nventa,Biopharmaceuticals Corporation ... lead therapeutic vaccine candidate for the treatment,of human papillomavirus (HPV)-related ...
... Detection of HPV Viral Load a Possible Indicator of Cervical ... ... Sept. 24 Cepheid (Nasdaq:,CPHD) today announced that it has entered ... held by Quantovir,AB of Sweden for the quantitative measurement of high-risk ...
... September 24 ProImmune Ltd., a leading,provider of quality ... antigen discovery, has announced the launch of its new,MHC-peptide ... the series of,discovery services for Class I HLA already ... binding assay for HLA alleles DR1-4, is a,powerful cell-free ...
Cached Biology Technology:Nventa announces publication of HspE7 data 2Nventa announces publication of HspE7 data 3Nventa announces publication of HspE7 data 4Nventa announces publication of HspE7 data 5Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB 2Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB 3Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB 4ProImmune Launches New MHC-Peptide Binding Assay for Class II HLA Alleles 2
(Date:6/30/2015)... 2015 To bolster its efforts and commitment to ... today the addition of two new team members. ... and David Raviv will act as head of ... commitment to providing the most secure solutions for the enterprise ... Layer 7 Technologies, a provider of security and management products, ...
(Date:6/25/2015)... , June 25, 2015  Imagine a tool ... toward a healthier, happier life. That,s exactly what USANA,s ... to do. The cutting-edge, portable health program provides a ... solutions to help improve your lifestyle and nutrition. ... dinner and gala Wednesday night, USANA,s THA was honored ...
(Date:6/24/2015)... , June 22, 2015 ... announced the addition of the "Huawei Ascend ... report to their offering. Huawei,s ... to the opposite direction than Apple,s and Samsung,s ... fingerprint sensor developed by Fingerprint Cards, a main ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... the Advancement of Science (AAAS) has named Dr. J. ... University of Colorado School of Medicine, as winner of ... Award., Cohen was honored for his outstanding achievements in ... series of free lectures on science and medicine, informal ...
... ANN ARBOR, Mich.---Rising carbon dioxide levels associated with global ... that eat them, altering the course of plant evolution, ... The research focused on the effects of elevated carbon ... of many plants that produce toxic or bitter chemical ...
... short stature is not usually cause for concern, but it ... syndrome. Prevalent in girls, Turner syndrome is a genetic defect ... problems. It is not commonly detected until age 10 or ... This lag before diagnosis of the condition can delay ...
Cached Biology News:Immunologist J. John Cohen receives the 2010 AAAS Public Understanding of Science and Technology Award 2Immunologist J. John Cohen receives the 2010 AAAS Public Understanding of Science and Technology Award 3Immunologist J. John Cohen receives the 2010 AAAS Public Understanding of Science and Technology Award 4Global warming may reroute evolution 2New test shows promise for accurate diagnosis of Turner syndrome 2
FEN-1 (B-4)...
Secure-Seal™ spacer, one well, 20 mm diameter, 0.12 mm deep *set of 100*...
Mouse monoclonal [2D7/1] to E.coli LPS ( Abpromise for all tested applications). Antigen: Tissue / cell preparation: Escherichia coli J5 cells....
Rat Antibody to Mouse TCR VB8.1,8.2:FITC Recognises the V beta 8.1 and V beta 8.2 determinants of the murine T cell receptor. Specificity: mouse TCR VB8.1 and 8.2...
Biology Products: